Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Andritz, Marinomed, Warimpex (09/12/2021)

12.12.2021

Andritz: International technology group ANDRITZ has received a repeat order from HKB-Hoa Lu Paper Joint Stock Company to supply a complete OCC line including reject treatment system for its mill in L Nho Quan District, Ninh Binh Province, Vietnam. Start-up is scheduled for the third quarter of 2022. The OCC line will have a design capacity of 500 t/d and process mixed OCC (Old Corrugated Containers) as raw material to produce high-quality testliner and corrugated medium for the Vietnamese and Chinese markets.
Andritz: weekly performance: 3.36%

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today a new study on the antiviral efficacy of iota-carrageenan (Carragelose) against the original SARS-CoV-2 strain and variants of concern (VOC), including the currently predominant Delta variant, has been published in the International Journal of Molecular Sciences. The peer-reviewed study is the result of a collaboration between virologists at the Friedrich-Alexander-Universität Erlangen- Nürnberg (FAU) and Marinomed as well as scientists from Ulm University Medical Center and the University Hospital Tuebingen who provided the patient-isolates of SARS-CoV-2 VOCs. In short, the study showed that iota-carrageenan was the most effective of the three carrageenans tested. At a concentration as low as 10 μg/ml, it was able to almost completely block virus replication in Calu-3 human lung cells for all SARS-CoV-2 strains tested, including the highly infectious delta variant.
Marinomed Biotech: weekly performance: -2.20%

Warimpex: Warimpex Finanz- und Beteiligungs AG announced the acquisition of a 10 per cent stake in the project company AO Avielen A.G. The seller is UBM Development AG, which has now fully withdrawn from the project. The parties involved agreed not to disclose the price. Warimpex now holds a stake of 100 per cent in Avielen, the project company responsible for the development and operation of Airportcity St. Petersburg. “Airportcity St. Petersburg is an important development project for us with tremendous potential. The acquisition of UBM’s minority stake represents the continuation of our activities at the location and can be interpreted as a clear commitment to the Russian market,” commented Franz Jurkowitsch, CEO of Warimpex.
Warimpex: weekly performance: 0.42%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (09/12/2021)


Partners









latest 21st Austria

21st Austria weekly - Andritz, Marinomed, Warimpex (09/12/2021)


12.12.2021, 2517 Zeichen



Andritz: International technology group ANDRITZ has received a repeat order from HKB-Hoa Lu Paper Joint Stock Company to supply a complete OCC line including reject treatment system for its mill in L Nho Quan District, Ninh Binh Province, Vietnam. Start-up is scheduled for the third quarter of 2022. The OCC line will have a design capacity of 500 t/d and process mixed OCC (Old Corrugated Containers) as raw material to produce high-quality testliner and corrugated medium for the Vietnamese and Chinese markets.
Andritz: weekly performance: 3.36%

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today a new study on the antiviral efficacy of iota-carrageenan (Carragelose) against the original SARS-CoV-2 strain and variants of concern (VOC), including the currently predominant Delta variant, has been published in the International Journal of Molecular Sciences. The peer-reviewed study is the result of a collaboration between virologists at the Friedrich-Alexander-Universität Erlangen- Nürnberg (FAU) and Marinomed as well as scientists from Ulm University Medical Center and the University Hospital Tuebingen who provided the patient-isolates of SARS-CoV-2 VOCs. In short, the study showed that iota-carrageenan was the most effective of the three carrageenans tested. At a concentration as low as 10 μg/ml, it was able to almost completely block virus replication in Calu-3 human lung cells for all SARS-CoV-2 strains tested, including the highly infectious delta variant.
Marinomed Biotech: weekly performance: -2.20%

Warimpex: Warimpex Finanz- und Beteiligungs AG announced the acquisition of a 10 per cent stake in the project company AO Avielen A.G. The seller is UBM Development AG, which has now fully withdrawn from the project. The parties involved agreed not to disclose the price. Warimpex now holds a stake of 100 per cent in Avielen, the project company responsible for the development and operation of Airportcity St. Petersburg. “Airportcity St. Petersburg is an important development project for us with tremendous potential. The acquisition of UBM’s minority stake represents the continuation of our activities at the location and can be interpreted as a clear commitment to the Russian market,” commented Franz Jurkowitsch, CEO of Warimpex.
Warimpex: weekly performance: 0.42%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (09/12/2021)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsenradio Live-Blick, Do. 25.4.24: DAX clincht mit 18000, Deutsche Bank, Mercedes, Commerzbank, VIG, Palfinger last 5 im TPT




 

Bildnachweis

Aktien auf dem Radar:Addiko Bank, Immofinanz, Marinomed Biotech, Flughafen Wien, Warimpex, EuroTeleSites AG, ATX Prime, ams-Osram, AT&S, Palfinger, RBI, Strabag, Pierer Mobility, UBM, CA Immo, Frequentis, Lenzing, SW Umwelttechnik, Oberbank AG Stamm, Wolford, Agrana, Amag, Erste Group, EVN, Kapsch TrafficCom, OMV, Österreichische Post, Telekom Austria, Uniqa, VIG, Wienerberger.


Random Partner

iMaps Capital
iMaps Capital ist ein Wertpapier- und Investmentunternehmen mit Schwerpunkt auf aktiv verwaltete Exchange Traded Instruments (ETI). iMaps, mit Sitz auf Malta und Cayman Islands, positioniert sich als Private Label Anbieter und fungiert als Service Provider für Asset Manager und Privatbanken, welche  ETIs zur raschen und kosteneffizienten Emission eines börsegehandelten Investment Produktes nutzen wollen.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten